# AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

> **NCT03453489** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Carcinoid Syndrome
- Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

## Interventions

- **OTHER:** Carbon C 11 Alpha-methyltryptophan
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Telotristat Etiprate

## Key facts

- **NCT ID:** NCT03453489
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2020-10-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03453489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03453489, "AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03453489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*